<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle">
<p class="DocumentTitle"><strong>URELLE- hyoscyamine sulfate, methenamine, methylene blue, phenyl salicylate and sodium phosphate, monobasic, monohydrateÂ tabletÂ </strong><br>Meda Pharmaceuticals Inc.<br></p>
<p class="disclaimer">Disclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. <a href="http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/EnforcementActivitiesbyFDA/SelectedEnforcementActionsonUnapprovedDrugs/default.htm">For further information about unapproved drugs, click here.</a></p>
</div>
<h1>
<span class="Bold">URELLE<span class="Sup">Â®</span></span><br><br>Urinary Antiseptic</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="AG100"></a><a name="section-1"></a><p></p>
<h1>DESCRIPTION:</h1>
<p class="First">Urelle<span class="Sup">Â®</span> tablets for oral administration are supplied as navy blue round tablets with â€œA-002â€? debossed on one side. </p>
<p>Each Tablet Contains: </p>
<p>Hyoscyamine Sulfate 0.12 mg </p>
<p>Methenamine 81.0 mg </p>
<p>Methylene Blue 10.8 mg </p>
<p>Phenyl Salicylate 32.4 mg </p>
<p>Sodium Phosphate Monobasic 40.8 mg<br><br></p>
<p><span class="Bold">INACTIVE INGREDIENTS:</span></p>
<p>Corn Starch, Dicalcium Phosphate, FD&amp;C Blue #2/Indigo Carmine Aluminum Lake, Magnesium Stearate, Microcrystalline Cellulose, Polyethylene Glycol, Polyvinyl Alcohol, Talc, Titanium Dioxide.</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="AG200"></a><a name="section-2"></a><p></p>
<h1>INDICATIONS and USAGE:</h1>
<p class="First">Urelle<span class="Sup">Â®</span> is indicated for the treatment of symptoms of irritative voiding. Indicated for the relief of local symptoms, such as <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span>, hypermotility, and <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, which accompany lower <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infections</span>. Indicated for the relief of urinary tract symptoms caused by diagnostic procedures.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="AG300"></a><a name="section-3"></a><p></p>
<h1>CONTRAINDICATIONS:</h1>
<p class="First"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> to any of the ingredients is possible. Risk - benefit should be carefully considered when the following medical problems exist: cardiac disease (especially <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">cardiac arrhythmias</span>, <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>, coronary heart disease, <span class="product-label-link" type="condition" conceptid="315273" conceptname="Mitral valve stenosis">mitral stenosis</span>); gastrointestinal tract obstructive disease; <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>; <span class="product-label-link" type="condition" conceptid="76685" conceptname="Myasthenia gravis">myasthenia gravis</span>; acute <span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">urinary retention</span> may be precipitated in <span class="product-label-link" type="condition" conceptid="194406" conceptname="Urinary tract obstruction">obstructive uropathy</span> (such as <span class="product-label-link" type="condition" conceptid="433813" conceptname="Bladder neck obstruction">bladder neck obstruction</span> due to <span class="product-label-link" type="condition" conceptid="198803" conceptname="Benign prostatic hyperplasia">prostatic hypertrophy</span>).</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="AG400"></a><a name="section-4"></a><p></p>
<h1>WARNINGS:</h1>
<p class="First"><span class="Bold">If rapid pulse, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, or <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurring of vision</span> occurs, discontinue use immediately.</span></p>
<p>Patients should be advised that urine will be colored blue when taking this medication. Do not exceed recommended dosage.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="AG500"></a><a name="section-5"></a><p></p>
<h1>PRECAUTIONS:</h1>
<p class="First">Cross sensitivity and/or related problems - patients intolerant of belladonna alkaloids or salicylates may be intolerant of this medication also. Delay in gastric emptying could complicate the management of <span class="product-label-link" type="condition" conceptid="4265600" conceptname="Gastric ulcer">gastric ulcers</span>.</p>
<p>Urelle<span class="Sup">Â®</span> contains methylene blue. Methylene blue should generally NOT be given to patients taking serotonergic drugs.</p>
<div class="Section" data-sectionCode="34076-0">
<a name="AG510"></a><a name="section-5.1"></a><p></p>
<h2 class="Italics">Drug Interactions:</h2>
<p class="First">Although the exact mechanism of this drug interaction is unknown, methylene blue inhibits the action of monoamine oxidase Aâ€” an enzyme responsible for breaking down serotonin in the brain. It is believed that when methylene blue is given to patients taking serotonergic psychiatric medications, high levels of serotonin can build up in the brain, causing toxicity. This is referred to as <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">Serotonin Syndrome</span>. Signs and symptoms of <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">Serotonin Syndrome</span> include mental changes (<span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="4137162" conceptname="Overactive">hyperactivity</span>, memory problems), <span class="product-label-link" type="condition" conceptid="4247265" conceptname="Muscle twitch">muscle twitching</span>, excessive <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>, <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">shivering</span> or <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">shaking</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, trouble with coordination, and/or <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="AG520"></a><a name="section-5.2"></a><p></p>
<h2 class="Italics">Additional Information for Healthcare Professionals: </h2>
<p class="First">Methylene blue can interact with serotonergic psychiatric medications and cause serious CNS toxicity.</p>
<p><span class="Underline">In emergency situations</span> requiring life-threatening or urgent treatment with methylene blue (as described above), the availability of alternative interventions should be considered and the benefit of methylene blue treatment should be weighed against the risk of serotonin toxicity. If methylene blue must be administered to a patient receiving a serotonergic drug, the serotonergic drug must be immediately stopped, and the patient should be closely monitored for emergent symptoms of CNS toxicity for two weeks (five weeks if fluoxetine [Prozac] was taken), or until 24 hours after the last dose of methylene blue, whichever comes first.</p>
<p><span class="Underline">In non-emergency situations</span> when non-urgent treatment with methylene blue is contemplated and planned, the serotonergic psychiatric medication should be stopped to allow its activity in the brain to dissipate. Most serotonergic psychiatric drugs should be stopped at least 2 weeks in advance of methylene blue treatment. Fluoxetine (Prozac), which has a longer half-life compared to similar drugs, should be stopped at least 5 weeks in advance.</p>
<p>Treatment with the serotonergic psychiatric medication may be resumed 24 hours after the last dose of methylene blue.</p>
<p>Serotonergic psychiatric medications should not be started in a patient receiving methylene blue. Wait until 24 hours after the last dose of methylene blue before starting the antidepressant.</p>
<p>Educate your patients to recognize the symptoms of serotonin toxicity or CNS toxicity and advise them to contact a healthcare professional immediately if they experience any symptoms while taking serotonergic psychiatric medications or methylene blue.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="AG600"></a><a name="section-6"></a><p></p>
<h1></h1>
<p class="First"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Meda Pharmaceuticals Inc. at 1-877-999-8402 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</span></p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="AG700"></a><a name="section-7"></a><p></p>
<h1>DOSAGE and ADMINISTRATION:</h1>
<p class="First">Adults â€“ One tablet orally 4 times per day followed by liberal fluid intake. </p>
<p>Pediatric â€“ Dosage must be individualized by a physician for older children. UrelleÂ® is not recommended for use in children 6 years of age or younger.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="AG800"></a><a name="section-8"></a><p></p>
<h1>HOW SUPPLIED:</h1>
<p class="First">Urelle<span class="Sup">Â®</span> tablets for oral administration are supplied in child resistant bottles of 90 tablets (NDC 0037-6321-90). </p>
<div class="Section" data-sectionCode="44425-7">
<a name="AG810"></a><a name="section-8.1"></a><p></p>
<p class="First">Store at controlled room temperature 20Â°-25Â°C (68Â°-77Â°F).</p>
<p>Dispense in a tight, light resistant container as defined in the USP.</p>
<p><span class="Bold">KEEP THIS AND ALL DRUGS OUT OF THE REACH OF CHILDREN. </span></p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="AG900"></a><a name="section-9"></a><p></p>
<h1></h1>
<p class="First">Distributed by: <br>
							Meda Pharmaceuticals<span class="Sup">Â®</span><br>
							Somerset, New Jersey 08873-4120
						</p>
<p>Â© 2014 Meda Pharmaceuticals Inc.</p>
<p>MEDA PHARMACEUTICALS and URELLE are registered trademarks of Meda AB or a related entity.</p>
<p>Rx Only</p>
<p>IN-632110-01</p>
<p>Rev. 07/2014</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="PDP1"></a><a name="section-10"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL â€“ BOTTLE LABEL</h1>
<p class="First">Description: Urelle<span class="Sup">Â®</span> tablets for oral administration are<br>
							supplied as navy blue round tablets with "A-002" debossed on<br>
							one side.
						</p>
<p>Each Tablet Contains:<br>
							Hyoscyamine Sulfate 0.12 mg<br>
							Methenamine 81.0 mg<br>
							Methylene Blue 10.8 mg<br>
							Phenyl Salicylate 32.4 mg<br>
							Sodium Phosphate Monobasic 40.8 mg
						</p>
<p>Dosage: Adults - one tablet orally 4 times per day followed by<br>
							liberal fluid intake. Pediatric - Dosage must be individualized by <br>
							a physician for older children. Urelle<span class="Sup">Â®</span> is not recommended for<br>
							use in children 6 years of age or younger.
						</p>
<p>Precaution: Contains Methylene Blue and should NOT be taken<br>
							with serotonergic psychiatric medications. For full product <br>
							information see package insert.
						</p>
<p>To report SUSPECTED ADVERSE REACTIONS, contact<br>
							Meda Pharmaceuticals Inc. at 1-877-999-8402 or FDA <br>
							at 1-800-FDA-1088 or www.fda.gov/medwatch.
						</p>
<p>Storage: Store at controlled room temperature 20Â°-25Â°C<br>
							(68Â°-77Â°F). Dispense in a tight, light resistant container as<br>
							defined in the USP.
						</p>
<p>KEEP OUT OF THE REACH OF CHILDREN.</p>
<p>NDC 0037-6321-90</p>
<p>90 TABLETS</p>
<p>urelle<span class="Sup">Â®</span></p>
<p>Urinary Antiseptic</p>
<p>Rx Only </p>
<p>Distributed by:<br>
							MEDA PHARMACEUTICALS<span class="Sup">Â®</span><br>
							Somerset, New Jersey 08873-4120
						</p>
<p>Â© 2014 Meda Pharmaceuticals Inc.</p>
<p>MEDA PHARMACEUTICALS and URELLE are registered trademarks of Meda AB or a related entity.</p>
<p>Note: Patients should be advised<br>
							that urine will be colored blue when<br>
							taking this medication.
						</p>
<p>LB-632110-01</p>
<p>Rev. 07/2014</p>
<p><img alt="Urelle Bottle Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=1d80a11c-6f86-403b-85d4-32ec1924dbe9&amp;name=urelle-figure-1.jpg"></p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>URELLEÂ 		
					</strong><br><span class="contentTableReg">hyoscyamine sulfate, methenamine, methylene blue, phenyl salicylate, and sodium phosphate, monobasic, monohydrate tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0037-6321</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>HYOSCYAMINE SULFATE</strong> (HYOSCYAMINE) </td>
<td class="formItem">HYOSCYAMINE SULFATE</td>
<td class="formItem">0.12Â mg</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>METHENAMINE</strong> (METHENAMINE) </td>
<td class="formItem">METHENAMINE</td>
<td class="formItem">81Â mg</td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>METHYLENE BLUE</strong> (METHYLENE BLUE CATION) </td>
<td class="formItem">METHYLENE BLUE</td>
<td class="formItem">10.8Â mg</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>PHENYL SALICYLATE</strong> (PHENYL SALICYLATE) </td>
<td class="formItem">PHENYL SALICYLATE</td>
<td class="formItem">32.4Â mg</td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE</strong> (PHOSPHATE ION) </td>
<td class="formItem">SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE</td>
<td class="formItem">40.8Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">BLUE</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND</td>
<td class="formLabel">Size</td>
<td class="formItem">11mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">A002</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0037-6321-90</td>
<td class="formItem">90  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">unapproved drug other</td>
<td class="formItem"></td>
<td class="formItem">01/12/2015</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>Meda Pharmaceuticals Inc.
							(051229602)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 1/2015<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>37b31a99-1a32-4e7f-9363-7061e1a20019</div>
<div>Set id: 1d80a11c-6f86-403b-85d4-32ec1924dbe9</div>
<div>Version: 1</div>
<div>Effective Time: 20150113</div>
</div>
</div>Â <div class="DistributorName">Meda Pharmaceuticals Inc.</div></p>
</body></html>
